FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 中國醫療集團有限公司 (以「萬全醫療集團」名稱在香港經營業務) (於開曼群島註冊成立之有限公司) 呈交日期: 2025年11月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 08225 | 說明 | | | | | | | | | 法定/註冊股份數目 | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | 10,000,000,000 | HKD | | 0.1 HKD | | 1,000,000,000 | | 增加 / 減少 (-) | | | 0 | | HKD | | 0 | | 本月底結存 | | 10,000,000,000 | HKD | | 0.1 HKD | | 1,000, ...

FF301 致：香港交易及結算所有限公司 公司名稱: 中國醫療集團有限公司 (以「萬全醫療集團」名稱在香港經營業務) (於開曼群島註冊成立之有限公司) 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 呈交日期: 2025年10月8日 截至月份: 2025年9月30日 狀態: 新提交 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 08225 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | HKD | | 0.1 HKD | | 1,000,000,000 | | 增加 / 減少 (-) | | | 0 | | | HKD | | 0 | | 本月底結存 | | | 10,000,000,000 | HKD | | 0.1 HKD | | 1, ...

Core Viewpoint - China Medical Group (08225) announced the appointment of executive director Guo Ruimeng as the company's authorized representative, effective from September 25, 2025 [1] Group 1 - The appointment of Guo Ruimeng is a strategic move for the company [1]

Core Points - China Medical Group (08225) announced the appointment of executive director Guo Ruimeng as the company's authorized representative, effective from September 25, 2025 [1] Company Summary - The appointment of Guo Ruimeng is a strategic move for the company, indicating a potential shift in leadership dynamics [1] - This change may impact the company's operational strategies and stakeholder relations moving forward [1]

格隆汇9月25日丨中国医疗集团(08225.HK)公告，执行董事郭瑞萌已获委任为公司授权代表，自2025年9 月25日起生效。 ...

（以「萬全醫療集團」名稱在香港經營業務） (於開曼群島註冊成立之有限公司) (股份代號: 08225) 授權代表的委任 中國醫療集團有限公司（「本公司」之董事會（「董事會」）謹此宣佈，執行董事郭瑞萌先生（「郭先生」）已獲 委任為本公司授權代表（「授權代表」），自二零二五年九月二十五日起生效。 董事會謹此熱烈歡迎郭先生出任授權代表新職務。 承董事會命 中國醫療集團有限公司 郭夏 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性或完備性亦無 發表聲明，並表明不會就本公告全部或任何部份內容或因倚賴該等內容而引致之任何損失承擔任何責任。 China Health Group Inc. 中國醫療集團有限公司 主席 香港，二零二五年九月二十五日 於本公告日期，董事會成員包括二名執行董事，分別為郭夏先生及郭瑞萌先生；一名非執行董事，為張麗博 士；及四名獨立非執行董事，分別為倪彬暉博士、伍霜駟先生、郭彤博士及劉娜女士。 本公告載有根據 GEM 上市規則規定須提供有關本公司資料的詳情，董事願就本公佈共同及個別地承擔全部責 任。各董事在作出一切合理查詢後確認，就彼等所知及所信，本公佈所載的資料在 ...

Financial Performance - For the six months ended June 30, 2025, the group recorded revenue of approximately RMB 21,620,000, an increase of about 18.19% compared to RMB 18,293,000 for the same period in 2024[3]. - The group achieved a profit before tax of approximately RMB 10,234,000, up approximately 18.30% from RMB 8,651,000 in the same period of 2024[3]. - Gross profit for the six months ended June 30, 2025, was RMB 13,945,000, with a gross margin of approximately 64.5%, compared to a gross margin of 65.5% in the same period of 2024[3]. - The net profit for the period was RMB 8,699,000, compared to RMB 7,353,000 for the same period in 2024[6]. - Basic and diluted earnings per share for the period were both 0.87 cents, compared to 0.74 cents in the same period of 2024[6]. - Total revenue for the six months ended June 30, 2025, increased by 18.19% to RMB 21,620,000 compared to RMB 18,293,000 in the same period of 2024[16]. - The pre-tax profit for the period was approximately RMB 10,234,000, up 18.30% from RMB 8,651,000 in the previous year[28]. - The net profit for the period was approximately RMB 8,699,000, representing an increase of 18.31% compared to RMB 7,353,000 in the same period last year[28]. Cash Flow and Assets - Cash and cash equivalents at the end of the period increased to RMB 23,732,000 from RMB 14,194,000 at the beginning of the period[8]. - The group reported net cash generated from operating activities of RMB 9,538,000, compared to RMB 2,883,000 in the same period of 2024[8]. - Total assets as of June 30, 2025, amounted to RMB 102,003,000, an increase from RMB 92,636,000 as of December 31, 2024[7]. - As of June 30, 2025, the company's net current assets were approximately RMB 70,400,000, compared to RMB 61,393,000 as of December 31, 2024[29]. - The company has no borrowings as of June 30, 2025, indicating a leverage ratio that is not applicable[29]. Expenses and Costs - Administrative expenses rose by 33.56% to RMB (1,389,000) from RMB (1,040,000) in the same period of 2024[18]. - The total administrative and employee costs amounted to approximately RMB 3,719,000, an increase of 12.02% from RMB 3,320,000 in the previous year[28]. - Employee compensation for the period amounts to approximately RMB 2,330,000, an increase from RMB 2,280,000 in the same period last year[54]. Dividends and Share Structure - The group did not declare any dividends for the six months ended June 30, 2025[3]. - The company did not recommend any dividend payment for the period, consistent with the previous year[21]. - The total number of issued shares as of June 30, 2025, is approximately 995,351,660 shares, with no changes in the capital structure during the period[47]. Corporate Governance - The board of directors confirmed that the information provided is accurate and complete, with no misleading elements[2]. - The company has complied with the corporate governance code, except for the separation of roles between the chairman and CEO, as the company has not appointed a CEO[81]. - The audit committee, consisting of four independent non-executive directors, has reviewed the unaudited consolidated results and confirmed compliance with applicable accounting standards[83]. - The board of directors includes two executive directors, one non-executive director, and four independent non-executive directors[85]. Strategic Focus and Development - The company is focused on providing integrated pharmaceutical services, including clinical research and post-market surveillance[10]. - The company aims to become a comprehensive service provider under an internet framework in the healthcare sector[10]. - The company aims to become a leader in real-world clinical research services, focusing on five major disease areas, leveraging real-world data (RWD), real-world studies (RWS), and artificial intelligence (AI)[25]. - The company is developing a "Research-based Treatment RWS-Therapy Model" and a "Digital Clinical Research Commercialization Organization (D-CRCO) Model" to redefine research-based treatment and commercialization[32]. - The company is committed to becoming a leading research and academic institution in the field of allergy treatment, with over 60% of allergy medications being developed through its clinical research center[34]. - The company has established partnerships with top medical institutions in cities like Beijing, Shanghai, and Guangzhou to develop digital specialty clinics and research areas[38]. - The company is focusing on big data clinical research to optimize existing medications for treating tobacco addiction and related diseases[37]. Stock Options and Equity - The stock option plan allows for a maximum of 30% of the issued shares to be issued upon exercise of all granted and unexercised options[70]. - The total number of shares available for issuance under the stock option plan is 88,947,166 shares, which is 8.94% of the total issued shares as of the interim results announcement date[71]. - Each eligible participant must pay HKD 1.00 when accepting an option offer, which must be paid within 21 days of the offer[76]. - There are no performance targets that must be met before exercising options unless decided by the board[72]. - Options can be exercised at any time within the period notified by the board, but not later than 10 years after the grant date[77]. - The exercise price of stock options must be at least the higher of the closing price on the grant date or the average closing price over the five trading days preceding the grant date[68]. - The total number of stock options granted during the period is 21,030,000, with no options exercised, canceled, or expired during this time[78]. - The exercise price for options granted on June 30, 2015, is HKD 0.450, while the exercise price for options granted on March 24, 2021, is HKD 0.504[78]. - Independent non-executive directors' options can be exercised immediately from March 24, 2021, while others have a one-year restriction[79]. Risk Management - The company closely monitors foreign currency risks, with most transactions denominated in RMB, and will hedge as necessary[49]. - The board will continue to manage cash prudently to maintain strong liquidity for future growth opportunities[50]. Subsequent Events - There have been no significant subsequent events reported after June 30, 2025, up to the date of this announcement[51]. Shareholding Structure - Winsland Agents Limited holds 349,368,873 shares, representing 35.10% of the company's equity[64]. - Venturepharm Holdings Inc. owns 149,432,583 shares, accounting for 15.01% of the company's equity[64]. - Bright Excel Assets Limited, a wholly-owned subsidiary of Venturepharm, holds 91,915,181 shares, which is 9.23% of the company's equity[64].

Core Insights - The company has successfully launched over ten AI-driven real-world research (AI-RWS) projects targeting prevalent mental health disorders among Chinese youth and elderly patients, marking a significant step in its strategic positioning within the "AI + clinical research" sector in Hong Kong [1] Academic and Research System - The forum gathered 40 leading experts in pediatric, adolescent psychiatry, and elderly cognitive disorders, establishing a comprehensive research system that integrates AI-driven classification, personalized treatment optimization, dynamic efficacy and safety predictions, and early relapse risk warnings [2] Key Sector Layout and Focus Products - **Youth Mental Health Sector**: The company initiated an AI-RWS study covering over 10,000 patients across 30 institutions in 15 cities, focusing on a population of over 30 million affected individuals. The study involves the exploration of combined treatments using its new drug group, which includes various formulations [3] - **Elderly Dementia and BPSD Sector**: The "Star Plan" aims to create the largest real-world database for BPSD in China, targeting 100,000 patients over five years, focusing on non-drug interventions and combination therapies to provide critical data for innovative drug registration and post-market safety evaluations [3] - The core clinical research products include the unique formulation of "Xienka Microtablet" which is recommended for treating mild to moderate dementia and is designed to address swallowing difficulties while showing superior efficacy compared to similar products [4] Commercialization Path and Future Outlook - The company employs a diversified funding model involving collaboration with research hospitals, pharmaceutical companies, government projects, and insurance co-payments, with project values ranging from millions to billions [5] - Future strategies include focusing on AI-RWS research and the development of intelligent physician assistants, aiming to become a global leader in the field while accelerating the transition to AI-driven clinical research services [5]

Core Insights - China Medical Group (08225) successfully held the "AI-RWS Real World Research Summit" in Shanghai, launching over ten AI-driven real-world research projects targeting high-prevalence mental disorders among Chinese youth and behavioral and psychological symptoms in dementia, marking a significant step in the company's strategic layout in the "AI + Clinical Research" sector, further consolidating its industry-leading position [1] Academic and Research System - The forum gathered 40 authoritative experts in pediatric, adolescent psychiatry, and geriatric cognitive disorders, learning from institutions like Stanford University and Mayo Clinic, and referencing the latest evidence-based guidelines from JAMA Psychiatry 2024 to construct a comprehensive research system integrating AI smart classification, personalized treatment path optimization, dynamic efficacy and safety prediction, and early warning of relapse risk [2] Core Sector Layout and Key Products - **Youth Mental Disorders Sector**: The company initiated an AI-RWS study covering over 30 institutions in 15 cities nationwide, targeting over 10,000 patients, focusing on the treatment of over 30 million affected youth in China. The study includes the exploration of combined or sequential treatments involving new drugs such as Xixin A, Xixin E, Xixin L, Xixin A, Xixin S, and Xixin L, aiming to optimize research protocols and predict disease progression [3] - **Dementia and BPSD Sector**: The "Star Plan" aims to build the largest and longest-followed BPSD real-world database in China, planning to include 100,000 patients over five years, focusing on non-drug interventions and combination therapies, providing critical data for innovative drug registration and post-marketing safety evaluations [3] - The company has obtained exclusive clinical research rights for key products like Xienka micro-patch and Xienmei flash tablets, which are recommended for treating mild to moderate dementia [4] Commercialization Path and Future Outlook - The company employs a diversified funding model involving collaboration with research hospitals, pharmaceutical companies, government projects, and insurance co-payments, with individual projects valued from millions to billions [5] - Leveraging platforms like Hainan Boao and Hengqin, the company can reduce the duration of Phase IV clinical studies by over 30%, aligning research outcomes with national health strategies, thus benefiting from policy advantages [5] - The company aims to focus on AI-RWS research and the development of intelligent physician agents, with core layouts in the Xixin mental health brand, Xien neurological brand, and Baimin allergic reaction brand, aspiring to become a global leader in the field and accelerate the transition to AI-driven clinical research services for enhanced shareholder value [5]

中國醫療集團有限公司（「本公司」欣然宣佈，近日於上海成功舉辦"AI -RWS 真實世界研究 高峰論壇"，並集中啟動十餘項針對中國青少年精神障礙、老年癡呆伴行為和心理症狀（BPSD） 兩大高發精神神經疾病的 AI 驅動真實世界研究（AI-RWS）專案 ，標誌著本公司在港股"AI+臨床 研究"賽道戰略佈局邁出關鍵一步，進一步鞏固行業領先地位。 一、學術與研究體系 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性或完備性亦無 發表聲明，並表明不會就本公告全部或任何部份內容或因倚賴該等內容而引致之任何損失承擔任何責任。 China Health Group Inc. 中國醫療集團有限公司 （以「萬全醫療集團」名稱在香港經營業務） (於開曼群島註冊成立之有限公司) (股份代號: 08225) 自願性公告之中國醫療集團之最新業務進展 本次論壇彙聚 40 位國內兒科、青少年精神醫學及老年認知障礙領域權威專家，並学习斯坦 福大學、梅奧醫學中心，參照《JAMA Psychiatry》2024 年最新循證指南，構建"AI 智能分型—個 性化治療路徑優化—療效與安全動態預測—復發風險早期預警"全週 ...